Last reviewed · How we verify
Hippuran I125 — Competitive Intelligence Brief
unknown
iodohippurate sodium I125
Nephrology
Live · refreshed every 30 min
Target snapshot
Hippuran I125 (iodohippurate sodium I125). Hippuran I125 works by binding to and being excreted by the kidneys, allowing for imaging of renal function.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Hippuran I125 TARGET | iodohippurate sodium I125 | unknown | iodohippurate sodium I125 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (iodohippurate sodium I125 class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Hippuran I125 CI watch — RSS
- Hippuran I125 CI watch — Atom
- Hippuran I125 CI watch — JSON
- Hippuran I125 alone — RSS
- Whole iodohippurate sodium I125 class — RSS
Cite this brief
Drug Landscape (2026). Hippuran I125 — Competitive Intelligence Brief. https://druglandscape.com/ci/iodohippurate-sodium-i125. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing